Myeloid lineage switch following CD7-targeted chimeric antigen receptor T-cell therapy in relapsed/refractory T-cell acute lymphoblastic leukemia

Ibrahim Aldoss,1 Parastou Tizro,2 Davsheen Bedi,3 James K. Mangan,4 Mary C. Clark,1 David Spencer,2 Joo Y. Song,2 Sindhu Cherian,6 Raju Pillai,2 Young Kim,2 Nitin Mahajan,7 Ketevan Gendzekhadze,4 Mike James,7 Kenneth Jacobs,7 Jan Davidson-Moncada,7 Stephen J. Forman,1 Huan-You Wang3 and Michelle Afkhami2

1Department of Hematology and Hematopoietic Cell Transplantation, Gehr Family Center for Leukemia Research, City of Hope, Duarte, CA; 2Department of Pathology, City of Hope, Duarte, CA; 3Department of Pathology, University of California San Diego, La Jolla, CA; 4Department of Medicine, Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California San Diego, La Jolla, CA; 5Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO; 6Department of Laboratory Medicine and Pathology, University of Washington, Seattle, WA; 7Wugen, Saint Louis, MO and 8HLA Laboratory, City of Hope, Duarte, CA, USA

Correspondence: I. ALDOSS - ialdoss@coh.org

https://doi.org/10.3324/haematol.2023.283566
Supplemental Figure 1. Timeline of key events. The patient was originally diagnosed with T-ALL and received the indicated therapies. Following initial response to CD7CAR T cells, the patient was diagnosed with acute myeloid leukemia that originated from the T-ALL as a likely lineage switch relapse. This figure was generated in BioRender.com.